Nectar Lifesciences is currently trading at Rs. 33.05, up by 0.55 points or 1.69% from its previous closing of Rs. 32.50 on the BSE.
The scrip opened at Rs. 32.80 and has touched a high and low of Rs. 33.55 and Rs. 31.80 respectively. So far 119645 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 35.00 on 09-Jun-2014 and a 52 week low of Rs. 9.65 on 06-Aug-2013.
Last one week high and low of the scrip stood at Rs. 35.00 and Rs. 29.00 respectively. The current market cap of the company is Rs. 715.39 crore.
The promoters holding in the company stood at 44.35% while Institutions and Non-Institutions held 14.87% and 20.26% respectively.
Nectar Lifesciences (NecLife) has touched a significant milestone by receiving second European cGMP (Current Good Manufacturing Practices) approval for its Cephalosporin Finished Dosage Forms (FDF) manufacturing facility in Baddi, Himachal Pradesh. NecLife has received second European cGMP compliance certification for both Oral & Injectables Cephalsporins followed by the successful inspection by the Portugal Authority - National Authority of Medicines and Health Products, Infarmed in July 2013. The Infarmed Certificate is accepted by all EU Health Authorities and by authorities of several other countries.
NecLife's FDF facility, Unit-VI, has received this approval for all the Cephalosporin steriles and Non-sterile products which includes tablets, capsule, powder for oral suspension and powder for injections. This approval is a testimony to the high standards of quality and compliance practices put in place by the company. This approval will facilitate exports to the lucrative generic drug markets of Europe and this certification opens up lot of opportunities for Contract Manufacturing for NecLife for European customers. In addition to EU approval NLL is eagerly awaiting USFDA approval in writing anytime for its FDF & API facility inspections by USFDA between January 12 and January 24, 2014.
Nectar Lifesciences is a $200 million pharmaceutical organization. The company offers a range of Cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1768.75 |
| Dr. Reddys Lab | 1337.30 |
| Cipla | 1448.00 |
| Lupin | 2155.25 |
| Zydus Lifesciences | 1000.80 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
